company background image
DC8A logo

DURECT DB:DC8A Stock Report

Last Price

€1.18

Market Cap

€35.2m

7D

0.9%

1Y

-71.5%

Updated

21 Mar, 2024

Data

Company Financials +

DC8A Stock Overview

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs.

DC8A fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

DURECT Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DURECT
Historical stock prices
Current Share PriceUS$1.18
52 Week HighUS$6.40
52 Week LowUS$0.41
Beta0.82
1 Month Change38.82%
3 Month Change185.02%
1 Year Change-71.50%
3 Year Change-92.76%
5 Year Change-79.55%
Change since IPO-99.26%

Recent News & Updates

Recent updates

Shareholder Returns

DC8ADE PharmaceuticalsDE Market
7D0.9%1.1%1.2%
1Y-71.5%-23.8%5.5%

Return vs Industry: DC8A underperformed the German Pharmaceuticals industry which returned -26.1% over the past year.

Return vs Market: DC8A underperformed the German Market which returned 4.9% over the past year.

Price Volatility

Is DC8A's price volatile compared to industry and market?
DC8A volatility
DC8A Average Weekly Movement15.4%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.0%
10% least volatile stocks in DE Market2.5%

Stable Share Price: DC8A's share price has been volatile over the past 3 months.

Volatility Over Time: DC8A's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199872Jim Brownhttps://www.durect.com

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

DURECT Corporation Fundamentals Summary

How do DURECT's earnings and revenue compare to its market cap?
DC8A fundamental statistics
Market cap€35.17m
Earnings (TTM)-€33.76m
Revenue (TTM)€8.47m

4.1x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DC8A income statement (TTM)
RevenueUS$9.19m
Cost of RevenueUS$35.27m
Gross Profit-US$26.07m
Other ExpensesUS$10.58m
Earnings-US$36.65m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 27, 2024

Earnings per share (EPS)-1.23
Gross Margin-283.57%
Net Profit Margin-398.65%
Debt/Equity Ratio129.8%

How did DC8A perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.